BPC 157 Phase 2 Trial Initiated to Accelerate Acute Hamstring Strain Repair
Background
Acute hamstring muscle strains are prevalent in athletes, causing significant time away from sport and a high risk of recurrence. Current rehabilitation protocols often fall short in accelerating tissue repair. Pentadecapeptide BPC 157 is an investigational peptide with preclinical evidence suggesting it influences pathways critical for tissue protection, angiogenesis, and overall repair processes, making it a promising candidate for musculoskeletal injuries.
Study Design
This is a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating BPC 157 for acute grade II hamstring muscle strain. Participants will receive either BPC 157 or placebo daily for 14 days, alongside a standardized rehabilitation program. Co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14. The trial is currently recruiting, with an estimated completion in 2028.
Why It Matters
This Phase 2 trial represents a significant step towards clinical validation for BPC 157 in human musculoskeletal injury. If successful, it could offer a novel therapeutic approach to accelerate recovery from acute hamstring muscle strains, potentially reducing athlete downtime and recurrence rates. The focus on both functional recovery and objective MRI-assessed structural healing provides a robust framework. Positive results could pave the way for BPC 157 as an adjunctive therapy in sports medicine rehabilitation protocols.